medical regulators

Japan is considering stricter regulations on regenerative medicine as treatments in the field proliferate across the country. The move follows growing concern that clinics are offering unproven therapies under looser rules than those governing conventional drugs. Officials are debating how to balance patient access to innovative treatments with safety oversight, and medical groups are watching closely for what the revised framework could mean for practice.

Heidi Overton, President Trump's nominee for FDA Commissioner, faced questioning from Senator Maggie Hassan at her confirmation hearing. Hassan pressed her on whether she would refuse an unlawful or improper directive from Trump, but Overton declined to entertain the possibility that the president could be wrong, drawing criticism that she would not commit to independent decision-making at the agency that regulates drugs and medical products.

Regulators in Vermont are receiving more detailed disclosure about how medical education is run in the state, following their calls for greater openness. The development follows demands from oversight bodies that had sought clearer information about medical training programs. Further details about what information is now being released, and how it will be used, remain limited.

Oregon state officials are warning residents about low-cost health insurance plans that provide far less coverage than consumers may expect. Regulators caution that these plans can leave people exposed to large medical bills when they actually need care. The alert comes during the period when residents are weighing their health coverage options, and officials are urging buyers to review what a plan actually covers before enrolling.